[디깅노트] 중국이 장악한 LO 시장, K바이오가 놓친 질문은

China now dominates 50% of the global biotech licensing market by deploying a volume-driven strategy with massive pipelines that Korean biotech cannot structurally replicate. K-biotech's mimicry of China's early-stage licensing approach is eroding its traditional strengths in clinical precision and data reliability instead of building sustainable competitive advantage. The industry must shift toward late-stage licensing and redefine competition around Korea's differentiated capabilities rather than competing on China's scale.